Kim Michelle J, Stinnett Sandra S, Gupta Preeya K
Department of Ophthalmology, Duke University Eye Center, Durham, NC, USA.
Clin Ophthalmol. 2017 May 9;11:883-886. doi: 10.2147/OPTH.S136203. eCollection 2017.
The goal of this study was to evaluate the effect of thermal pulsation treatment on tear film parameters, specifically osmolarity and matrix metalloproteinase-9 (MMP-9), in patients with meibomian gland dysfunction (MGD) and dry eye disease (DED).
A single-center review of 189 eyes that underwent thermal pulsation treatment was performed. Data were collected on pre and posttreatment osmolarity, MMP-9, tear break-up time (TBUT), and ocular surface disease index (OSDI) score. Statistical analyses were performed to detect any significant differences after treatment.
Thermal pulsation treatment led to significant improvements in TBUT (mean increase from 4.5 to 8.5 seconds [<0.001]), OSDI score (mean decrease from 50.5 to 41.6 [=0.024]), and MMP-9 (50% positive rate pretreatment compared to 26% positive rate post treatment [<0.0001]). In the subset of patients who had a baseline osmolarity >307 mOsm/L (ie, diagnostic for DED), there was a significant improvement in the mean tear osmolarity from 317.1 to 306.6 mOsms/L after treatment (=0.002).
Treating MGD is an important component of caring for the DED patient. Thermal pulsation treatment can improve MMP-9 levels on the ocular surface of patients with MGD and DED, as well as improve osmolarity in those with abnormal initial values. The present study suggests that meibomian glands play an important role in tear film dynamics and, as such, effective therapy such as thermal pulsation treatment aimed at improving meibomian gland health, can aid the restoration of normal tear film parameters and decrease patient symptoms of DED and MGD.
本研究的目的是评估热脉动治疗对睑板腺功能障碍(MGD)和干眼病(DED)患者泪膜参数的影响,特别是渗透压和基质金属蛋白酶-9(MMP-9)。
对189只接受热脉动治疗的眼睛进行单中心回顾性研究。收集治疗前后的渗透压、MMP-9、泪膜破裂时间(TBUT)和眼表疾病指数(OSDI)评分数据。进行统计分析以检测治疗后是否有任何显著差异。
热脉动治疗使TBUT(平均从4.5秒增加到8.5秒[<0.001])、OSDI评分(平均从50.5降至41.6[=0.024])和MMP-9(治疗前阳性率为50%,治疗后为26%[<0.0001])有显著改善。在基线渗透压>307 mOsm/L(即诊断为DED)的患者亚组中,治疗后平均泪渗透压从317.1 mOsm/L显著改善至306.6 mOsm/L(=0.002)。
治疗MGD是护理DED患者的重要组成部分。热脉动治疗可改善MGD和DED患者眼表的MMP-9水平,并改善初始值异常患者的渗透压。本研究表明睑板腺在泪膜动力学中起重要作用,因此,旨在改善睑板腺健康的有效治疗方法,如热脉动治疗,可有助于恢复正常泪膜参数并减轻DED和MGD患者的症状。